Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT04414618
Previous Study | Return to List | Next Study

A Study of Opaganib in Coronavirus Disease 2019 Pneumonia (COVID-19)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04414618
Recruitment Status : Completed
First Posted : June 4, 2020
Last Update Posted : March 10, 2021
Sponsor:
Information provided by (Responsible Party):
RedHill Biopharma Limited

Tracking Information
First Submitted Date  ICMJE May 26, 2020
First Posted Date  ICMJE June 4, 2020
Last Update Posted Date March 10, 2021
Actual Study Start Date  ICMJE July 2, 2020
Actual Primary Completion Date November 26, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: December 16, 2020)
Measurement of the oxygen requirement [ Time Frame: 14 days ]
To compare the total oxygen requirement (area under the curve) for each arm using daily supplemental oxygen flow (L/min) over 14 days
Original Primary Outcome Measures  ICMJE
 (submitted: May 29, 2020)
Evaluation of the total oxygen requirement (area under the curve) using daily supplemental oxygen flow (L/min) over 14 days [ Time Frame: Every day from day 1 to day 14 of treatment ]
Measurement of the oxygen requirement
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: December 16, 2020)
  • Measurement of the reduction in oxygen requirement. [ Time Frame: 14 days ]
    To comparing the time required between arms to achieve 50% reduction from baseline in supplemental oxygen based on oxygen flow in L/min
  • Eliminating supplemental oxygen [ Time Frame: 14 days ]
    To comparing the proportion of patients in each arm no longer requiring supplemental oxygen for at least 24 hours by Day 14
  • Elimination of fever [ Time Frame: 14 days ]
    To compare the proportion of afebrile patients in each arm at Day 14 via measurement of temperature.
  • Time to negative swabs for SARS-CoV-2 by PCR post treatment [ Time Frame: 6 weeks ]
    To compare the time in each arm to negative swabs for SARS-CoV-2 by PCR nasopharyngeal or oropharyngeal swab for SARS-CoV-2
  • Time to negative swabs for SARS-CoV-2 by PCR at Day 14 [ Time Frame: 14 days ]
    To comparing the time in each arm to achieve negative swabs for SARS-CoV-2 by PCR nasopharyngeal or oropharyngeal swab for SARS-CoV-2 during treatment
  • Intubation and mechanical ventilation requirements [ Time Frame: From screening phase and every day from day 1 to day 14 of treatment ]
    To compare the percentage of patients in each arm who require intubation and mechanical ventilation by Day 14
  • Evaluation of the time to mechanical ventilation [ Time Frame: From screening phase and every day from day 1 to day 14 of treatment ]
    To compare the time in each arm for the patient to require mechanical ventilation.
  • Evaluation the proportion of patients, with at least one measurement of fever at baseline who are afebrile at Day 14 [ Time Frame: From screening phase and every day from day 1 to day 14 of treatment ]
    To compare the proportion of patients in each arm, with at least one measurement of fever at baseline (defined as temperature >38.0 C[100.4 F]), who are afebrile (defined as temperature <37.2C [99 F]) at Day 14
  • Evaluation of mortality 30 days post-baseline [ Time Frame: 30 days after day 1 of treatment ]
    To compare the mortality in each arm 30 days post-baseline.
Original Secondary Outcome Measures  ICMJE
 (submitted: May 29, 2020)
  • Evaluation of the time to 50% reduction from baseline in supplemental oxygen based on oxygen flow in L/min [ Time Frame: Every day from day 1 to day 14 of treatment ]
    Measurement of the oxygen requirement
  • Evaluation of the proportion of patients no longer requiring supplemental oxygen for at least 24 hours by Day 14 [ Time Frame: From screening phase and every day from day 1 to day 14 of treatment ]
  • Evaluation of the proportion of afebrile patients at Day 14 [ Time Frame: From screening phase and every day from day 1 to day 14 of treatment ]
    Measurement of temperature
  • Evaluation of the time to negative swabs for SARS-CoV-2 by PCR [ Time Frame: From screening phase and every day from day 1 to day 14 of treatment and at the end of the 4 weeks follow-up after the end of treatment ]
    Nasopharyngeal or oropharyngeal swab for SARS-CoV-2
  • Evaluation of the proportion of patients with negative swabs for SARS-CoV-2 by PCR at Day 14 [ Time Frame: From screening phase and every day from day 1 to day 14 of treatment and at the end of the 4 weeks follow-up after the end of treatment ]
    Nasopharyngeal or oropharyngeal swab for SARS-CoV-2
  • The percentage of patients who require intubation and mechanical ventilation by Day 14 [ Time Frame: From screening phase and every day from day 1 to day 14 of treatment ]
  • Evaluation of the time to mechanical ventilation [ Time Frame: From screening phase and every day from day 1 to day 14 of treatment ]
  • Evaluation the proportion of patients, with at least one measurement of fever at baseline who are afebrile at Day 14 [ Time Frame: From screening phase and every day from day 1 to day 14 of treatment ]
    Evaluation the proportion of patients, with at least one measurement of fever at baseline (defined as temperature >38.0 C[100.4 F]), who are afebrile (defined as temperature <37.2C [99 F]) at Day 14
  • Evaluation of mortality 30 days post-baseline [ Time Frame: 30 days after day 1 of treatment ]
Current Other Pre-specified Outcome Measures
 (submitted: January 21, 2021)
  • Safety TEAEs [ Time Frame: 6 weeks ]
    To compare the number of all treatment-emergent adverse events in each arm of all treatment-emergent adverse events (TEAEs).
  • Safety SAEs [ Time Frame: 6 weeks ]
    To measure all serious adverse events (SAEs) in each arm.
Original Other Pre-specified Outcome Measures
 (submitted: May 29, 2020)
To determine the incidence rate of all treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) [ Time Frame: Every day from day 1 to day 14 of treatment and at end of the 4 weeks follow-up after the end of treatment ]
 
Descriptive Information
Brief Title  ICMJE A Study of Opaganib in Coronavirus Disease 2019 Pneumonia
Official Title  ICMJE Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia: a Randomized, Double-blind, Placebo-Controlled Phase 2a Study, in Adult Subjects Hospitalized With SARS-CoV-2 Positive Pneumonia
Brief Summary This proof of concept study will take place in the US and other countries in approximately 15 clinical sites and will enroll about 40 hospitalized patients diagnosed with COVID-19 infection who have developed pneumonia and require supplemental oxygen. 20 patients will receive opaganib in addition to standard of care twice each day for 14 days. 20 will receive matching placebo in addition to standard of care unless the patient has been discharged from the hospital without requiring supplemental oxygen, in which case study drug will only be administered for 10 days. All participants will be followed up for 4 weeks after their last dose of study drug.
Detailed Description Opaganib, a sphingosine kinase-2 (SphK2) inhibitor, has been broadly tested in Phase I/II studies. Extensive nonclinical data indicates both anti-viral and anti-inflammatory activity via selective SphK2 inhibition which may prove beneficial for treating COVID-19 infection and resulting pneumonia. This proof of concept study will take place in the US and other countries and will enroll about 40 hospitalized patients diagnosed with COVID-19 infection who have developed pneumonia and require supplemental oxygen. Half of the patients, i.e. 20 patients, will receive opaganib in addition to standard of care for 14 days. The other 20 will receive matching placebo (capsules that do not contain the medication) in addition to standard of care. Study drug will be administered every day for 14 days, twice each day, unless the patient has been discharged from the hospital without requiring supplemental oxygen, in which case study drug will only be administered for 10 days. All participants will be followed up for 4 weeks after their last dose of study drug.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Coronavirus Infections
Intervention  ICMJE
  • Drug: Opaganib
    Study participants will receive either opaganib 2 x 250 mg capsules (500 mg) every 12 hours, in addition to standard of care (pharmacological and/or supportive).
    Other Names:
    • Yeliva
    • ABC294640
  • Drug: Placebo
    Study participants will receive placebo 2 x 250 mg capsules (500 mg) every 12 hours, in addition to standard of care (pharmacological and/or supportive).
Study Arms  ICMJE
  • Active Comparator: opaganib
    Study participants will receive opaganib 2 x 250 mg capsules (500 mg) plus standard of care every 12 hours
    Intervention: Drug: Opaganib
  • Placebo Comparator: placebo
    Study participants will receive placebo 2 x 250 mg capsules (500 mg) plus standard of care every 12 hours
    Intervention: Drug: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: January 28, 2021)
42
Original Estimated Enrollment  ICMJE
 (submitted: May 29, 2020)
40
Actual Study Completion Date  ICMJE December 23, 2020
Actual Primary Completion Date November 26, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Adult male or female ≥18 to ≤80 years of age
  2. Proven COVID-19 infection per RT-PCR assay of a pharyngeal sample (nasopharyngeal or oropharyngeal) AND pneumonia defined as radiographic opacities on chest X-ray
  3. The patient requires supplemental oxygen at baseline
  4. The patient, guardian or legal representative has signed a written IRB-approved informed consent.

5) Male participants with female partners of child-bearing potential agree to one of the following methods of contraception during the treatment period and for at least 1 month after the last dose of study drug:

  • Abstinence from penile-vaginal intercourse and agree to remain abstinent.
  • Male condom, with female partner using a highly effective contraceptive method. (For further details regarding highly effective contraceptive methods please see section 9.3.)

In addition, male participants must refrain from donating sperm for the duration of the study and for 1 months after last dose of study drug.

Male participants with a pregnant or breastfeeding partner must agree to remain abstinent from penile-vaginal intercourse or use a male condom during each episode of penile penetration for at least 1 months after the last dose of study drug

Female participants:

A female participant is eligible to participate if she is:

  1. not pregnant
  2. not breastfeeding
  3. not a woman of child-bearing potential (WOCBP, as defined in Section 9.3)
  4. a WOCBP who agrees to use a highly effective method of contraception consistently and correctly during the treatment period and for at least 1 months after the last dose of study drug (please see further details on Section 9.3).

Exclusion Criteria:

  1. Any co-morbidity that may add risk to the treatment in the judgement of the investigator.
  2. Requiring intubation and mechanical ventilation
  3. Patient having a do not intubate or do not resuscitate order
  4. Oxygen saturation >95% on room air
  5. Any preexisting respiratory condition that requires intermittent or continuous ambulatory oxygen prior to hospitalization
  6. Patient is, in the investigator's clinical judgment, unlikely to survive >72 hours
  7. Pregnant or nursing women
  8. Unwillingness or inability to comply with procedures required in this protocol.
  9. Corrected QT (QTc) interval on electrocardiogram (ECG) >470 ms for females or >450 ms for males, calculated using Friedericia's formula (QTcF)
  10. AST (SGOT) or ALT (SGPT) > 2.5 x upper limit of normal (ULN)
  11. Bilirubin >2.0 x ULN (except where bilirubin increase is due to Gilbert's Syndrome)
  12. Serum creatinine >2.0 X ULN
  13. Absolute neutrophil count <1000 cells/mm3
  14. Platelet count <75,000/mm3
  15. Hemoglobin <8.0 g/dL
  16. Currently taking medications that are sensitive CYP3A4, CYP1A2, CYP2C9, or CYP2C19 or CYP2D6 substrates and have a narrow therapeutic index. These should be decided in discussion with the Medical Monitor on a case-by-case basis.
  17. Currently taking medications that are strong inducers or inhibitors of CYP2D6 and CYP3A4. These should be decided in discussion with the Medical Monitor on a case-by-case basis.
  18. Currently taking warfarin, apixaban, argatroban or rivaroxaban.
  19. Current drug or alcohol abuse.
  20. Currently participating in a clinical study assessing pharmacological treatments, including anti-viral studies.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 80 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Israel,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04414618
Other Study ID Numbers  ICMJE ABC-110
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party RedHill Biopharma Limited
Study Sponsor  ICMJE RedHill Biopharma Limited
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Mark L Levitt, MD, PhD RedHill Biopharma Limited
PRS Account RedHill Biopharma Limited
Verification Date March 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP